# A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

> **NCT06196879** · PHASE2 · COMPLETED · sponsor: **Upstream Bio Inc.** · enrollment: 479 (actual)

## Conditions studied

- Severe Asthma

## Interventions

- **DRUG:** Verekitug (UPB-101)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06196879
- **Lead sponsor:** Upstream Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-27
- **Primary completion:** 2025-12-16
- **Final completion:** 2026-03-19
- **Target enrollment:** 479 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196879, "A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06196879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*